ClinicalTrials.gg
RecruitingNCT07097740POLYVALVE-FIHUpdated Jul 31, 2025

Early Feasibility Study of Surgical Implantation of a Polymer Prosthetic Mitral and Aortic Valve

An interventional study of Polymer Prosthetic Heart Valve in AORTIC VALVE DISEASES, Mitral Valve Disease and Aortic Stenosis, sponsored by Mitrassist Lifesciences Limited Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Mitrassist Lifesciences Limited Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Aortic Valve Disease with a site in China — 16 open to participants now, 18 under way, none of them phase 3. Aortic Valve Disease · China.

Planned enrollment
12th of 14
10 · median 98
Started
2025
with 3 others
No phase
12 of 27
4 open now
Primary completion
2026-06
later than 5 of 17 live
Registered
22nd of 27
by date

Among the 27 studies in Aortic Valve Disease with a site in China, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 with no phase, reaches primary completion later than 5 of the 17 other live ones, and was the 22nd registered.

Aortic Valve Disease

234 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

16 of the 27 studies in Aortic Valve Disease with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Aortic Valve Disease with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to explore the early feasibility, initial safety, and efficacy of surgical implantation of a polymer prosthetic heart valve in patients requiring either mitral valve replacement or aortic valve replacement.

The main question it aims to answer is:

-- What is the rate of valve-related complications, including thromboembolism, valve thrombosis, severe perivalvular leak, severe bleeding, and endocarditis, at 12 months post-operation?

Participants will undergo:

  • Surgical implantation of a polymer prosthetic valve (mitral valve replacement for mitral valve group and aortic valve replacement for aortic valve group).
  • Regular follow-up visits at 30 days, 3-6 months, and 12 months post-operation to evaluate clinical outcomes, including echocardiographic assessment and clinical event monitoring.
Read the detailed description

This is a prospective, exploratory, single-center clinical study designed to assess the early feasibility and initial safety of an investigational polymer prosthetic heart valve. A total of 10 patients will be enrolled, with 5 patients assigned to the mitral valve replacement group and 5 patients to the aortic valve replacement group.

Primary outcomes include the occurrence of valve-related complications within 12 months, such as thromboembolism, valve thrombosis, severe perivalvular leak, severe bleeding, and endocarditis.

Secondary outcomes include immediate device success rate, valve hemodynamic performance, comprehensive safety event evaluations (e.g., all-cause mortality, all-cause reoperation, valve extraction, and structural or non-structural valve dysfunction), cardiac functional classification (NYHA), and quality of life assessments (Kansas City Cardiomyopathy Questionnaire, KCCQ).

Eligible participants are patients requiring mitral or aortic valve replacement, capable of undergoing extracorporeal circulation and anticoagulation therapy, and who have provided informed consent.

Exclusion criteria include patients with prior valve replacement surgery (except transcatheter mitral valve edge-to-edge repair), urgent/emergency procedures, significant comorbidities (e.g., recent stroke or myocardial infarction, severe liver/kidney dysfunction, active infections), severe coagulation disorders, allergies to valve materials, substance abuse issues, psychiatric disorders, or anticipated life expectancy under 12 months. Patients who drop out after valve implantation will not be replaced.

03

Conditions studied

  • AORTIC VALVE DISEASES
  • Mitral Valve Disease
  • Aortic Stenosis
  • Aortic Regurgitation
  • Mitral Stenosis
  • Mitral Regurgitation
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults requiring surgical replacement of either mitral or aortic valve
  • Capable of undergoing cardiopulmonary bypass
  • Able to tolerate anticoagulation therapy
  • Able to understand study purpose, willing to provide and comply with follow-up

Exclusion criteria

Exclusion Criteria:

  1. History of previous cardiac valve surgery or percutaneous valve replacement, including surgical aortic or mitral valve replacement (excluding Percutaneous Balloon Mitral Valvuloplasty [PBMV], which is permitted).
  2. Requirement for urgent or emergency cardiac surgery.
  3. Planned concurrent aortic valve surgery or combined valve procedure (e.g., simultaneous aortic and mitral valve surgery).
  4. Scheduled coronary artery bypass graft (CABG) during the same admission.
  5. Anticipated need for additional non-valve cardiac surgery within 12 months.
  6. Active systemic infection, including pneumonia or infective endocarditis.
  7. Intracardiac thrombus detected on echocardiography or imaging.
  8. Stroke or within the prior 3 months.
  9. Myocardial infarction, unstable coronary syndrome, or coronary revascularization within the prior 3 months.
  10. Severe comorbidities with expected \<12 months, including C liver disease, end-stage , or advanced pulmonary disease.
  11. Participation in another interventional clinical trial involving devices or drugs.
  12. Anatomical risk factors such as ascending aortic aneurysm (≥50 mm), bicuspid aortic valve with ascending aorta ≥45 mm, or other high-risk features identified on imaging.
  13. (LVEF) ≤35%, indicating severe systolic dysfunction.
  14. Severe renal insufficiency, e.g., estimated \<30 mL/min/1.73 m² or requirement for chronic dialysis.
  15. Coagulopathy or active bleeding disorders, e.g., >1.5 without anticoagulation therapy.
  16. Hematologic abnormalities: hematocrit \<30%, \<100 g/L, count \<100 × 10⁹/L, or WBC \<4 × 10⁹/L or >10 × 10⁹/L.
  17. History of substance abuse, chronic alcoholism, or significant psychiatric illness impairing study compliance.
  18. Preoperative or intraoperative anatomical unsuitability of the valve apparatus or cardiac structure.
  19. Known allergy or to polyurethane, polyester, or sulfonate-based biomaterials used in the valve prosthesis.
  20. Withdrawal from the study after valve implantation (such participants are not allowed to re-enroll).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Polymer Aortic Valve Replacement

    Surgical implantation of polymer prosthetic valve in the aortic position.

    Device: Polymer Prosthetic Heart Valve

  • Experimental
    Polymer Mitral Valve Replacement

    Surgical implantation of polymer prosthetic valve in the mitral position.

    Device: Polymer Prosthetic Heart Valve

Interventions

  • DevicePolymer Prosthetic Heart Valve

    Surgical implantation of polymer prosthetic valve.

06

What researchers measure

Primary outcomes

  1. 12-Month Incidence of Valve-related Complications

    Evaluate the incidence of valve-related complications at 12 months post-operation, including thromboembolism, valve thrombosis, severe perivalvular leak, severe bleeding, and endocarditis.

    Time frame: 12 months post-operation

Secondary outcomes

  1. Immediate Device Success Rate

    Proportion of participants achieving successful device implantation without intraoperative complications.

    Time frame: Immediately post-operation

  2. Valve Hemodynamic Performance 1 Mean Transvalvular Gradient at 12 months

    Mean pressure gradient across the valve measured by echocardiography (unit: mmHg).

    Time frame: 12 months post-operation

  3. Valve Hemodynamic Performance2 Effective Orifice Area (EOA) at 12 months

    Effective orifice area of the implanted valve measured by echocardiography (unit: cm²).

    Time frame: 12 months post-operation

  4. Safety Outcomes and Adverse Events

    Incidence of safety-related events including all-cause mortality, all-cause reoperation, valve extraction, valve thrombosis, severe bleeding, severe perivalvular leak, structural and non-structural valve deterioration, hemolysis, endocarditis, and any other serious adverse events.

    Time frame: Up to 12 months post-operation

  5. Cardiac Function Classification (NYHA)

    Assess participants' cardiac function using New York Heart Association (NYHA) classification.

    Time frame: 12 months post-operation

  6. Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score at 12 months

    Quality of life assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ is a 23-item questionnaire measuring health status in heart failure patients, scored from 0 to 100, where higher scores indicate a better health status.

    Time frame: 12 months post-operation

  7. Valve Hemodynamic Performance 3 Paravalvular Leakage Severity at 12 months

    Severity of paravalvular leakage (PVL) assessed by echocardiography, classified as None/Trace, Mild, Moderate, or Severe.

    Time frame: 12 months post-operation

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200000, China
    Recruiting
    • Lai Wei, MD · Contactwei.lai@zs-hospital.sh.cn · 021-51371990
    • Chunsheng Wang, MD · Principal investigator
    • Lai Wei, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 61 interventional studies with no phase under Aortic Valve Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 61. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 31, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2027
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07097740
Lead sponsor
Mitrassist Lifesciences Limited Co., Ltd.
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Jun 27, 2025
Primary completion
Jun 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 31, 2025

Study contacts

Lai Wei, MD
Contact
wei.lai@zs-hospital.sh.cn
021-51371990
Chunming Du, Medical Master
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion